Two Russian-developed peptides usually described as a matched pair.
Related origins, different intent. Semax derives from ACTH(4-10) and is discussed for attention and cognition; Selank derives from tuftsin and is discussed for anxiety. Both carry Russian clinical use behind them, which is why both sit in the clinical tier despite thin Western literature.
| Semax | Selank | |
|---|---|---|
| What it is | ACTH(4-7)-Pro-Gly-Pro | Tuftsin analogue, Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Evidence tier | Clinical | Clinical |
| Route | Subcutaneous | Subcutaneous |
| Half-life | Short | Short |
| Vial sizes | 10 mg | 10 mg |
| Water we suggest | standard rule | 3 mL |
| Reported doses | 200 mcg, 400 mcg, 600 mcg | 250 mcg, 500 mcg, 750 mcg |
| Has a schedule | no | no |
The clinical record for both is largely Russian-language and not indexed the way Western trials are. Treat the tier as reflecting real clinical use rather than the kind of published trial you can pull up and read.
The Semax / Selank blend exists because the two are commonly combined. Its figures are per compound — a 500 mcg total is 250 mcg of each.